جست‌وجوی استاد و پژوهشگر

Qun Sophia Zangمشاهده پروفایل

دانشیار

• Cardiology
• Immunology
• Cell Biology
• +۳ مورد دیگر

Qun Sophia Zang is an Associate Professor at the Stritch School of Medicine, Loyola University Chicago, within the Department of Microbiology and Immunology. Her primary affiliation is the Burn & Shock Trauma Research Institute and the Center for Translational Research and Education. Her research focuses on sepsis-induced cardiac dysfunction, mitochondrial biology, and autophagy mechanisms. Dr. Zang leads a multidisciplinary team investigating how mitochondrial-derived danger signals (DAMPs) and metabolic reprogramming contribute to multi-organ failure in sepsis. Her work combines preclinical models with clinical insights to identify novel therapeutic targets. Research Interests: Dr. Zang's lab explores the role of autophagy factors like Beclin-1 in mitochondrial quality control, metabolic plasticity shifts in sepsis, and age-related susceptibility to septic cardiomyopathy. Current projects include studying Beclin-1's regulation of mitophagy, mitochondrial-associated membranes (MAMs), and how myocardial metabolites interact with immune cells during infection. Publications: Her recent work emphasizes mitochondrial dysfunction in sepsis, autophagy-protective strategies, and sex-based differences in cardiac responses to inflammation. Her methods include genetic models, targeted metabolomics, and translational studies using neonatal/elderly sepsis models. Affiliations: Active member of the Burn & Shock Trauma Research Institute, Loyola's Center for Translational Research, and collaborates with clinical teams on translational medicine initiatives. Funded by NIH grants focusing on sepsis pathophysiology and cardiac protection mechanisms. Labs/Teams: Directs a lab focused on mitochondrial biology and sepsis, training students in preclinical disease modeling and interdisciplinary research.

• Cardiovascular Physiology
• Neuroendocrinology
• Metabolic Regulation
• +۵ مورد دیگر

Alexandre Alves da Silva is an Assistant Professor in the Department of Physiology and Biophysics at the University of Mississippi Medical Center School of Medicine. His research program focuses on elucidating the molecular and cellular mechanisms by which the central nervous system, particularly the melanocortin system pathway, regulates glucose homeostasis and cardiovascular function. Dr. da Silva maintains active collaborations within the Cardiorenal and Metabolic Diseases Research Center and serves as a Sub-Core Leader for the Imaging Core. Dr. da Silva earned his BS and PhD in Physiology from the University of Sao Paulo, Brazil, followed by postdoctoral training at the University of Mississippi Medical Center. His academic appointments include positions as Instructor (2001-2006), Assistant Professor (2006-2014), and current Assistant Professor (2018-present) at UMMC, with a brief period (2015-2017) as Professor at Brazilian institutions Centro Universitario Barao de Maua and Universidade Estadual de Minas Gerais. His research interests center on the CNS control of metabolic and cardiovascular function, with particular emphasis on the brain melanocortin system's role in protecting cardiac function after myocardial infarction and maintaining glucose homeostasis in diabetic conditions. His laboratory employs sophisticated techniques including perfused hearts for cardiac metabolic studies, isolated cardiomyocytes for contractility measurements, and genetic mouse/rat models for in vivo physiological studies. Recent work has expanded to investigate the intergenerational effects of parental obesity on offspring cardiometabolic health. Analysis of his recent publications reveals a strong trend toward understanding the neural mechanisms underlying cardiometabolic protection, with increasing focus on sex differences, immunometabolism, and mitochondrial function in cardiac and renal injury. His work bridges basic neuroscience with translational cardiology, aiming to develop novel CNS-targeted therapies for heart failure and diabetes complications. 2023 Ad-Hoc grant reviewer, Swiss National Foundation 2022 Grant reviewer, NIH Therapeutic Develop and Pre-Clinical Studies 2018 Fujifilm-VisualSonics Vevo® Travel Award in Cardiac Imaging 2017 Marcos Augusto Award, Centro Universitario Barao de Maua 2012-present Fellow of the American Heart Association 2007 Excellence in Research Award Bronze Level – UMMC Dr. da Silva currently serves as Principal Investigator on multiple NIH grants including R01HL163076 'Cardiac protective mechanisms of melanocortin system activation' (2023-2026) and previously led a COBRE Pilot Grant on CNS mechanisms of cardiac protection. His laboratory collaborates extensively within the Cardiorenal and Metabolic Diseases Research Center, contributing to infrastructure for multidisciplinary research on obesity-related diseases. While specific students aren't listed in the provided materials, his research program clearly supports multiple postdoctoral fellows and graduate students involved in his NIH-funded projects. His laboratory is integrated within the Cardiometabolic and Imaging Core facilities at UMMC, utilizing advanced techniques including perfused heart systems, cardiomyocyte isolation, and in vivo physiological monitoring. The research environment benefits from collaborations with the Cardiorenal and Metabolic Diseases Research Center, providing access to specialized core facilities and multidisciplinary expertise in obesity, cardiovascular, and metabolic research.

Jody Haighمشاهده پروفایل

استاد

• Leukemia Research
• Epigenetic Therapy
• Cellular Plasticity
• +۷ مورد دیگر

Dr. Jody Haigh is a Professor in the Department of Pharmacology and Therapeutics at the Max Rady College of Medicine, University of Manitoba. He leads a research group at the Research Institute in Oncology and Hematology (RIOH), focusing on leukemia and cellular plasticity. His work involves investigating ZEB/SNAI transcription factors in blood cell development, identifying novel therapies for aggressive blood cancers, and exploring regenerative medicine applications. Education: BSc (Honours) in Life Sciences (Queen’s University, 1992), MSc in Biochemistry (Queen’s Cancer Research Institute, 1995), PhD in Biochemistry (IMP/University of Vienna, 2000). Postdoctoral training at Mount Sinai Hospital (2000–2004). Prior academic roles include positions at Ghent University (Belgium) and Monash University (Australia). Research Themes: Cellular plasticity in cancer and regeneration Leukemia biology and therapeutic targeting Epigenetic modulation in hematopoietic systems Generation of transgenic mouse models Publications: Over 90 peer-reviewed articles in journals like Blood , Nature , and Nature Communications , with >7,000 citations. Recent work emphasizes ZEB2’s role in leukemia progression and novel combination therapies. Awards: Larkins Fellowship (Monash University), Terry Fox Postdoctoral Fellowship, and Vienna Biocentre PhD Studentship. His research is supported by grants from CancerCare Manitoba and the University of Manitoba. Labs/Teams: Leads the Haigh Lab at RIOH, collaborating with the Manitoba Epigenetics Network. Actively mentors students in PhD and Master’s programs, focusing on hematological malignancies and regenerative strategies.

Xiao Qingzhongمشاهده پروفایل

استاد

• Stem Cell Biology
• Cardiovascular Disease
• Vascular Development
• +۳ مورد دیگر

Professor Xiao Qingzhong is a Professor of Stem Cell and Cardiovascular Disease at Queen Mary University of London's William Harvey Research Institute (WHRI), within the Faculty of Medicine and Dentistry. He leads an independent research lab focusing on stem cell biology, vascular development, and cardiovascular disease mechanisms. His academic career includes roles as Senior Lecturer (2013) and Reader (2016) before becoming Chair Professor in 2018. Education & Early Career: He earned a Bachelor of Medicine from Chongqing University of Medical Sciences (1994), followed by a Master's (Medical Immunology) and PhD (Pathology) from Sun Yat-Sen University (1999–2003). Postdoctoral training at St George's and King's College London (2003–2009) focused on stem cell differentiation into vascular cells. In 2010, he joined WHRI with a British Heart Foundation (BHF) fellowship to establish his research program. Research Focus: His lab explores molecular mechanisms governing vascular cell differentiation from stem cells, with applications in cardiovascular therapies. Key areas include: Identifying signaling pathways (e.g., microRNAs, transcription factors) regulating endothelial/smooth muscle cell differentiation. Role of non-coding RNAs in stem cell pluripotency and vascular biology. Stem cell therapy for cardiovascular diseases like atherosclerosis and restenosis. Proteinases (e.g., MMP8, NE) in atherosclerosis progression and macrophage polarization. Cellular reprogramming for vascular regeneration. Awards & Funding: Recipient of the BHF Intermediate Basic Science Fellowship (2010). Current grants include BHF project funding. Collaborators include Prof Qingbo Xu (King's College), Prof Shu Ye, and international teams at Zhejiang University and Tsinghua University. Lab Team & Training: Supervised over 20 PhD students and postdoctoral researchers (e.g., Dr Wei Wu, Dr Weiwei An). Current students include Eithne Maguire and Shiping He. Alumni hold academic and clinical roles globally. Publications: Over 150 peer-reviewed articles, including high-impact studies in Circulation Research , Cardiovascular Research , and Journal of Biological Chemistry . Recent work highlights novel roles for Nrf3, miRNAs, and mechanosensing in vascular pathology.

Kate Weeksمشاهده پروفایل

عضو هیئت علمی

• Molecular Cardiology
• Protein Phosphatases
• Cardiac Remodelling
• +۳ مورد دیگر

Dr. Kate Weeks is an Adjunct Lecturer at the Baker Heart and Diabetes Institute, leading the Molecular Cardiology Group. Her research focuses on protein phosphatase regulatory subunits' role in cardiac remodelling and heart failure, using in vivo mouse models, molecular biology, and omic technologies. She holds a PhD in Biochemistry from the University of Melbourne (2012) and has received prestigious fellowships including the Heart Foundation Overseas Research Fellowship and Baker Institute Emerging Leader Fellowship. Her work addresses translational therapies for heart failure and contributes to UN SDG 3 (Good Health and Well-Being). Research interests include molecular cardiology, protein phosphatase signaling, and diabetic cardiomyopathy. Recent work examines maternal diet's impact on offspring cardiovascular outcomes and estrogen receptor deficiencies in cardiomyocytes. Awards include grants from Diabetes Australia and The Shine On Foundation. Dr. Weeks collaborates internationally across institutions like King's College London and has published 14 peer-reviewed articles since 2010.

Michael A. O'Reillyمشاهده پروفایل

استاد

• Developmental Origins of Disease
• Neonatal Lung Injury
• Hyperoxia
• +۷ مورد دیگر

Michael A. O'Reilly, Ph.D., is a Professor in the Department of Pediatrics (Neonatology) and the Department of Environmental Medicine at the University of Rochester School of Medicine and Dentistry. His research focuses on the developmental origins of cardiopulmonary disease, particularly how neonatal hyperoxia affects lung and heart development, host defense, and long-term health outcomes. Dr. O'Reilly earned his BS in Biology from SUNY Stony Brook in 1984 and his PhD in Developmental Biology from the University of Cincinnati in 1989. He completed postdoctoral training at the NIH under Drs. Michael Sporn, Anita Roberts, Heiner Westphal, and Kathleen Mahon. His research interests include oxidative stress, DNA damage signaling, alveolar epithelial biology, mitochondrial function, and the impact of early-life oxygen exposure on lung regeneration and immune responses. He has made significant contributions to understanding how p21 protects against oxidative stress independent of cell cycle arrest and how neonatal hyperoxia reprograms stem cells, leading to persistent lung and cardiovascular disease. His recent publications (2020–2025) focus on neonatal hyperoxia effects on cardiopulmonary health, viral host defense, metabolic reprogramming, and neurovascular injury. These studies reveal consistent themes of mitochondrial dysfunction, altered progenitor cell differentiation, and long-term organ damage following early oxygen exposure. Ruth A. Lawrence Academic Faculty Service Award Dean's Incentive Award (2004–2008) National Research Council Fellowship Albert B. Ryan Fellowship NIH Training Grant Dr. O'Reilly has mentored numerous graduate students and postdoctoral fellows, many of whom have advanced to successful academic and industry positions. His lab collaborates across disciplines, including immunology, virology, and environmental health sciences. He is actively involved in the Environmental Health Sciences Center and the Immunology, Microbiology, and Virology PhD program at the University of Rochester. The O'Reilly Lab investigates how abnormal oxygen environments at birth disrupt lung and heart development. Key projects include studying hyperoxia effects on alveolar epithelial cells, host defense against influenza, cardiovascular disease development, and immune dysfunction in ataxia telangiectasia mutated lung disease.

Conrad L Eptingمشاهده پروفایل

دانشیار

• Critical Care Medicine
• Pediatric Cardiology
• Regenerative Medicine
• +۳ مورد دیگر

Conrad L Epting, MD, serves as Associate Professor in the Department of Pediatrics (Critical Care) with secondary appointment in Pathology at Northwestern University's Feinberg School of Medicine. He maintains active affiliations with the Institute for Public Health and Medicine (IPHAM) - Osher Center for Integrative Health, Northwestern University Clinical and Translational Sciences Institute (NUCATS), and Stanley Manne Children's Research Institute, reflecting his translational research focus. His research spans Critical Care Medicine, Pediatric Cardiology, and Regenerative Medicine, with significant contributions to cardiac reprogramming techniques and inflammation mechanisms during pediatric cardiac surgery. Additional work in molecular parasitology examines Trypanosoma brucei enzyme functions, demonstrating interdisciplinary expertise bridging clinical pediatrics and basic science. Recent publications (2021-2023) reveal a strategic focus on cardiovascular regeneration through stem cell approaches and critical analysis of cardiopulmonary bypass complications. His parasitology work identifies novel lipase functions in trypanosomal metabolism, highlighting therapeutic target potential. These publications collectively emphasize molecular mechanisms underlying cardiac and infectious disease processes. Dr. Epting maintains professional transparency through annual industry disclosures, including 2024 ownership interest in Vivacelle Bio, Inc. His research environment leverages Northwestern's integrated institutes for public health, clinical translation, and children's research, facilitating collaborative approaches to pediatric critical care challenges.

Riikka Martikainenمشاهده پروفایل

استاد پژوهشی

• Mitochondrial diseases
• Stem cell research
• Neurodegenerative diseases
• +۷ مورد دیگر

Riikka Martikainen serves as a Research Director at the A.I. Virtanen Institute for Molecular Sciences within the Faculty of Health Sciences at the University of Eastern Finland. Her research program focuses on mitochondrial diseases, stem cell modeling, and neurodegenerative disorders, with particular expertise in Parkinson's disease mechanisms and mitochondrial DNA mutations. She leads significant research initiatives including the Neuro-Innovation project (2021-2026) and the NOVEL MSCA Postdoctoral Programme (2024-2029), demonstrating her leadership in both specific research domains and broader capacity-building efforts. Dr. Martikainen's research centers on understanding mitochondrial dysfunction in disease contexts using induced pluripotent stem cell (iPSC) technology to model conditions like Parkinson's disease, progressive myoclonic epilepsy, and mitochondrial disorders. Her laboratory investigates how mtDNA mutations affect cellular function across various tissue types, with particular attention to neuronal and cardiac cells. She explores the interplay between mitochondrial dysfunction, metabolic alterations, and neurodegenerative processes, seeking to identify potential therapeutic targets and develop disease-specific cellular models. Analysis of her recent publications reveals a strong emphasis on developing and characterizing disease-specific iPSC lines, investigating mitochondrial heteroplasmy dynamics, and examining cellular responses to mitochondrial dysfunction. Her work spans from basic mechanisms of mitochondrial DNA maintenance to translational applications in disease modeling and potential therapeutic interventions, with particular focus on astrocyte contributions to Parkinson's pathology, mitochondrial mutation effects on cellular metabolism, and innovative approaches to modulate mtDNA heteroplasmy. Dr. Martikainen's laboratory utilizes advanced techniques including iPSC derivation and differentiation, mitochondrial function assays, calcium imaging, metabolomics, and disease modeling. Her collaborative approach is evident in numerous co-authorships across neuroscience, cardiology, and molecular biology disciplines, reflecting the interdisciplinary nature of her research program focused on bridging basic molecular mechanisms with potential clinical applications.

• Cardiac Metabolism
• Diabetes Mellitus
• Mitochondrial Dynamics
• +۴ مورد دیگر

Evan Dale Abel is Professor and Chair of the Department of Medicine at the David Geffen School of Medicine, University of California, Los Angeles (UCLA). His research program, substantially funded by the NIH, investigates molecular mechanisms linking metabolic disorders like diabetes to cardiovascular complications. Key focus areas include cardiac insulin resistance, mitochondrial dynamics in heart failure, and the impact of oxidative stress on diabetic cardiomyopathy. Abel's work spans fundamental metabolic pathways in cardiac and skeletal muscle, exploring how disruptions in glucose uptake, insulin/IGF-1 signaling, mitochondrial function (e.g., involving OPA1, GLUT proteins), and autophagy contribute to disease pathogenesis. His recent publications demonstrate a strong emphasis on translating basic discoveries in mitochondrial bioenergetics, autophagy regulation, and metabolic reprogramming into understanding human conditions like heart failure and type 2 diabetes. Research trends highlight the integration of advanced techniques, including metabolomics, electron microscopy analysis, and in vivo physiological modeling. He leads significant NIH grants, including R01 awards focused on molecular determinants of MG53 in heart function, modulating ROS via electromagnetic fields for type 2 diabetes treatment, OPA1's role in platelet hyperactivation, and diabetes research training. His laboratory investigates therapeutic strategies targeting metabolic pathways and oxidative stress in cardiovascular tissues.

• Cardiovascular Research
• Cardiology
• Vascular Diseases
• +۵ مورد دیگر

Tomohiro Yokota is an Assistant Professor-in-residence in the Department of Medicine at the University of California, Los Angeles (UCLA) School of Medicine. His research focuses on cardiovascular biology, particularly cardiac development, repair mechanisms, and the molecular pathways underlying heart disease. Dr. Yokota's research interests span cardiovascular research, cardiology, vascular diseases, molecular biology, heart development and repair, cardiac physiology, cardiac regeneration, and exercise physiology. His work investigates how molecular mechanisms regulate cardiac development and repair processes, with particular emphasis on extracellular matrix components, metabolic pathways, and signaling cascades that influence heart function and disease progression. He has made significant contributions to understanding how exercise modulates cardiovascular health, the role of collagen in cardiac scar formation, and the molecular pathways involved in cardiac maturation and regeneration. His publication record shows consistent productivity with research spanning from 2012 to the present, including high-impact publications in journals such as Cell, Nature Medicine, Circulation Research, and Journal of Clinical Investigation. His work demonstrates strong interdisciplinary collaboration across multiple laboratories at UCLA, with research spanning basic molecular mechanisms to potential clinical applications. Dr. Yokota has received significant attention for his work, with several publications picked up by multiple news outlets, blogged about, and shared extensively on social media platforms. His research on Type V Collagen in Scar Tissue, in particular, has been widely recognized with coverage from 15 news outlets, 11 blog posts, 43 X (Twitter) posts, a Reddit mention, and a video feature, with 126 readers on Mendeley. His collaborative network at UCLA is extensive, working closely with researchers including Arjun Deb, Tzung Hsiai, Aldons Lusis, Michael Teitell, and Matteo Pellegrini. His research bridges basic science and clinical applications, focusing on translating molecular discoveries into potential therapeutic approaches for cardiovascular diseases.

• Mitochondrial Metabolism
• Cancer Biology
• B Cell Development
• +۷ مورد دیگر

Dr. Michael Teitell, MD, PhD, is a tenured Associate Professor at University of California, Los Angeles (UCLA) in the Department of Pathology and Laboratory Medicine . He serves as Chief of the Division of Pediatric and Neonatal Pathology and holds board certification in anatomic, clinical, and pediatric pathology. His academic journey includes an MSTP MD/PhD at UCLA , postdoctoral work with Dr. Mitchell Kronenberg, and clinical pathology training at UCSF/Brigham and Women's Hospital. Education: B.S./M.S. in Chemistry & Biochemistry (UCLA 1985), MD/PhD (UCLA 1993) Academic Appointments: Assistant Professor (1999), Associate Professor (2004), Chief of Pediatric Pathology (current) His research spans mitochondrial metabolism , TCL1 oncogene mechanisms in lymphomas, and nanoscale cellular analysis using live-cell interferometry. Recent work explores mitochondrial transfer in disease models and clinical trial diversity barriers through consent document translation costs. Key Research Themes: Linking mitochondrial dynamics to B cell differentiation and lymphomagenesis Developing bioengineered tools for stem cell and cancer cell analysis Epigenetic regulation in hematologic malignancies Addressing health disparities in clinical trial enrollment Scientific Awards: David Paul Kane Scholar (1999-2000) Leukemia and Lymphoma Society Scholar (2003-2008) NIH Nanomedicine Development Center Award Election to American Society for Clinical Investigation (2004) His 15 most recent articles (2019-2025) focus on mitochondrial biology, stem cell metabolism, cancer signaling, and bioengineered imaging techniques. These publications reveal trends in mitochondria-related disease mechanisms , nanoscale cellular dynamics , and metabolic regulation in tumor microenvironments .

• Immunology
• Cardiology
• Pathology
• +۵ مورد دیگر

Andrew H. Lichtman is a Professor of Pathology at Brigham and Women's Hospital . He holds concurrent appointments in the Department of Pathology, focusing on cross-disciplinary research at the intersection of immunology and cardiovascular disease. Education: BA in Biology from Bowdoin College (1974) MD/PhD in Medicine/Biophysics from University of Rochester (1981) Residency in Pathology at Brigham and Women's Hospital (1986) Research Focus: Lichtman's work explores immune regulation in cardiovascular diseases, particularly: T cell biology in atherosclerosis and myocarditis Mechanisms of PD-1/PD-L1 pathways in cardiac protection Cancer immunotherapy -associated cardiac toxicity Role of immune checkpoints like LAG3 and CTLA4 Platelet-immune system interactions Publications reveal a strong emphasis on: Mouse models of vascular inflammation Immunometabolic mechanisms in heart failure Cross-presenting immune cells in tumor responses Translational work in clinical immunology and infectious disease

• Stem Cells
• Induced Pluripotent Stem Cells
• Neurodegenerative Diseases
• +۳ مورد دیگر

James R Dutton is an Associate Professor at the University of Minnesota's Stem Cell Institute with a joint appointment in the Department of Genetics, Cell Biology and Development. He also serves as a Research Manager 3, leading multiple NIH-funded projects focused on neurodegenerative diseases and regenerative medicine through 2027. His research explores stem cell applications in human disease modeling and therapy, with expertise in: Induced pluripotent stem cell (iPSC) reprogramming and differentiation Molecular mechanisms of neurodegenerative disorders (ALS, FTD, SCA1) Retinal degeneration pathophysiology and therapeutic targets Neural stem cell-mediated CNS regeneration RNA localization and cellular protrusion dynamics Recent publications (2024-2025) demonstrate strong focus on: Stem cell preservation techniques and protocol development Genetic regulation in evolutionary contexts Therapeutic pathways for age-related macular degeneration Molecular basis of oxidative stress in retinal diseases He currently advises graduate students including Walker, K.E. and Nathan Kochen, and leads six active NIH grants exploring: SCA1 pathogenesis in cerebellar organoids TDP43 restoration for ALS/FTD treatment Neural crest RNA localization mechanisms Alpha-synuclein monitoring technologies Thrombin receptor targeting for CNS regeneration

George A. Porterمشاهده پروفایل

استاد

• Cardiac Development
• Mitochondrial Biology
• Pediatric Cardiology
• +۳ مورد دیگر

George A. Porter, M.D., Ph.D. is Professor of Pediatrics, Cardiology at the University of Rochester School of Medicine and Dentistry. He holds the Rhea and Raymond White Professorship in Pediatric Cardiology and serves as Chief of the Department of Pediatrics, Cardiology. Additionally, he maintains joint appointments as Professor in the Department of Medicine, Aab Cardiovascular Research Institute and Department of Pharmacology and Physiology. Dr. Porter is actively engaged in clinical care, research, and teaching at the University of Rochester Medical Center, with patients rating him highly (4.8/5 stars). Dr. Porter earned his MD and PhD from the University of Maryland School of Medicine in 1994 and 1993 respectively, following undergraduate studies at the University of Notre Dame. He completed pediatric training at Yale University, including internship (1994-1995), residency (1995-1997), and fellowship in Pediatric Cardiology (1997-2000). His research laboratory investigates cardiac development mechanisms with emphasis on mitochondrial roles in cardiac myocytes. Using mouse models, his team discovered that mitochondrial permeability transition pore (PTP) closure between early and mid-embryonic periods triggers mitochondrial maturation, activates oxidative phosphorylation, and reduces oxidative stress, signaling further myocyte differentiation. Recent work extends these findings to neonatal hearts, showing PTP closure enhances cardiac function. Dr. Porter also leads the University of Rochester site for the NIH Pediatric Cardiac Genomics Consortium, which has enrolled over 10,000 congenital heart disease patients for genetic studies. Analysis of Dr. Porter's recent publications reveals an expanding research scope from basic mitochondrial biology to genomic approaches and neurodevelopmental outcomes in congenital heart disease. His work increasingly integrates machine learning with multi-omics data to understand genetic mechanisms and predict clinical outcomes, while maintaining focus on mitochondrial regulation of cardiac development and function. Mentor of the Year Award (2018) Ruth A. Lawrence Academic Faculty Service Award in Research (2015) Second place, Basic Cardiovascular Science Poster Competition (2008) The Mae Gailani Junior Faculty Award (2004) AHA Travel Award to the 1999 Weinstein Cardiovascular Development Conference Dr. Porter's research has been funded by the Charles H. Hood Foundation, Children's Cardiomyopathy Foundation, American Heart Association, NIH, Pfizer, Strong Children's Research Center, and University of Rochester institutes. As Chief of Pediatric Cardiology and site PI for the Pediatric Cardiac Genomics Consortium, he mentors numerous trainees and collaborates internationally. His laboratory is embedded within the Aab Cardiovascular Research Institute ecosystem, maintaining strong connections with the NIH Bench to Bassinet program and global pediatric cardiology networks. Dr. Porter's research team employs multidisciplinary approaches combining molecular biology, genetics, physiology, and computational methods. The laboratory maintains active collaborations with the Cardiovascular Development Consortium and participates in international research networks focused on pediatric cardiology and mitochondrial biology, with recent expansion into brain-heart axis investigations.

Brian L. Linمشاهده پروفایل

استادیار

• Muscular Dystrophy
• Cardiac Dysfunction
• Mechanical Signaling
• +۵ مورد دیگر

Brian L. Lin, PhD is an Assistant Professor in the Department of Cell Biology, Neurobiology, and Anatomy at the Medical College of Wisconsin. His research focuses on mechanical signaling in the heart within muscular dystrophy contexts, addressing cardiac dysfunction which is a leading cause of mortality in these diseases. He holds a PhD from Loyola University (2016) and a BS from Miami University (2008), with postdoctoral training at Johns Hopkins Medical Institutions (2016-2023). Education : BS, Miami University, 2008 PhD, Loyola University, 2016 Postdoctoral Fellow, Johns Hopkins Medical Institutions, 2023 Research Focus : The Lin Lab employs spatial transcriptomics, animal models, single-cell biomechanics, and nanoparticle drug delivery to develop therapies targeting TRP channels in dystrophic cardiomyopathy. Key areas include cardiac mechanical signaling, TRPC6 channel inhibition, and stem cell engineering for regenerative medicine. Publications : Recent work emphasizes drug discovery (e.g., ruxolitinib repurposing), gene therapy limitations, cadmium toxicity effects, and TRP channel pharmacology. Publications span Science Translational Medicine , Cell Reports , and iScience . Awards : K99/R00 Award (TRPC6 in Duchenne Muscular Dystrophy) Lab & Collaborations : The lab integrates multi-omics approaches with preclinical testing platforms. Current projects explore novel therapies using in silico drug discovery and human stem cell models. Follow @iheartlinlab for updates.